Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
167 hedge funds and large institutions have $2.56B invested in Acceleron Pharma in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 58 reducing their positions, and 27 closing their positions.
395% more call options, than puts
Call options by funds: $38.9M | Put options by funds: $7.86M
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
29% more capital invested
Capital invested by funds: $1.98B → $2.56B (+$579M)
2% less funds holding
Funds holding: 170 → 167 (-3)
11% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 27
12% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$123M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.1M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$21.6M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$22.3M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$21M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$19.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$16.9M |
| 5 |
Morgan Stanley
New York
|
-$8.32M |
XLRN Hedge Fund Activity: Q3 2018 in Review
167 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2018, worth a combined $2.56B — up 29% from $1.98B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of XLRN and 24 opened new positions — a net loss of 3 holders — while 58 trimmed existing stakes and 51 added.
The largest buyer was Fidelity Investments, adding an estimated $123M. The largest seller was Novo Holdings A/S, cutting an estimated $22.3M.
- 167 institutional investors held Acceleron Pharma (XLRN) as of Q3 2018, down from 170 in Q2 2018.
- Funds reported $2.56B of Acceleron Pharma stock for Q3 2018, up 29% quarter-over-quarter.
- 24 funds opened new Acceleron Pharma positions in Q3 2018 and 27 closed out, a net change of -3 holders.
- The largest Acceleron Pharma buyer in Q3 2018 was Fidelity Investments, an estimated $123M added.
- The largest Acceleron Pharma seller in Q3 2018 was Novo Holdings A/S, an estimated $22.3M sold.
Based on aggregated 13F filings for Q3 2018.